Keywords: dendreon, cancer, vaccine, misses, endpoint, company, stays

Dendreon cancer vaccine misses endpoint, but company stays positive

Article | 19 August 2002

Print This

Dendreon of the USA has reported preliminary results from its Phase IIItrial of Provenge (APC 8015), an investigational vaccine for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in